E5501: phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancer

被引：0
|
作者：
Taofeek K. Owonikoko
Joseph Aisner
Xin Victoria Wang
Suzanne E. Dahlberg
Eric H. Rubin
Suresh S. Ramalingam
Murugesan Gounder
Paul Gregory Rausch
Rita S. Axelrod
Joan H. Schiller
机构：
[1] Emory University,Department of Biostatistics
[2] Rutgers Cancer Institute of New Jersey,Department of Biostatistics
[3] Harvard School of Public Health,undefined
[4] Dana–Farber Cancer Institute,undefined
[5] Merck Research Laboratories,undefined
[6] Frederick Memorial Hospital,undefined
[7] Thomas Jefferson University,undefined
[8] University of Texas Southwestern Medical Center,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2014年 / 73卷
关键词：
Small cell; Topoisomerase; Clinical trial; Topotecan; Irinotecan; Sequential administration; Survival;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：171 / 180
页数：9
相关论文
共 50 条
  • [21] A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer
    Tabata, Masahiro
    Kiura, Katsuyuki
    Okimoto, Niro
    Segawa, Yoshihiko
    Shinkai, Tetsu
    Yonei, Toshiro
    Kuyama, Shoichi
    Harita, Shingo
    Hotta, Katsuyuki
    Ueoka, Hiroshi
    Tanimoto, Mitsune
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 60 (01) : 1 - 6
  • [22] Comparison of Amrubicin and Weekly Cisplatin/Etoposide/Irinotecan in Patients With Relapsed Small-cell Lung Cancer
    Okuma, Hitomi Sumiyoshi
    Horinouchi, Hidehito
    Kitahara, Shinsuke
    Asao, Tetsuhiko
    Sunami, Kuniko
    Goto, Yasushi
    Kanda, Shintaro
    Fujiwara, Yutaka
    Nokihara, Hiroshi
    Yamamoto, Noboru
    Ohe, Yuichiro
    CLINICAL LUNG CANCER, 2017, 18 (02) : 234 - +
  • [23] A comparative study on etoposide combined with lobaplatin or cisplatin in the first-line treatment of extensive-stage small cell lung cancer
    Li, Shujun
    Liang, Yahai
    Wu, Yanxia
    Huang, Zhong
    Lin, Yanming
    Yang, Zhixiong
    Chen, Hualin
    Wu, Aibing
    JOURNAL OF BUON, 2020, 25 (03): : 1490 - 1496
  • [24] Phase II Study of Irinotecan Plus Cisplatin as First Line therapy in Extensive Small-Cell Lung Cancer
    Hwang, Ki Eun
    Kim, So Young
    Jung, Jong Hoon
    Park, Seong Hoon
    Park, Jung Hyun
    Kim, Hwi Jung
    Kim, Hak Ryul
    Yang, Sei Hoon
    Jeong, Eun Taik
    TUBERCULOSIS AND RESPIRATORY DISEASES, 2006, 61 (02) : 143 - 149
  • [25] Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung carcinoma - A Phase II trial of the North Central Cancer Treatment Group
    Jett, JR
    Hatfield, AK
    Hillman, S
    Bauman, MD
    Mailliard, JA
    Kugler, JW
    Morton, RF
    Marks, RS
    Levitt, R
    CANCER, 2003, 97 (10) : 2498 - 2503
  • [26] A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer
    Schelman, William R.
    Mohammed, Tabraiz A.
    Traynor, Anne M.
    Kolesar, Jill M.
    Marnocha, Rebecca M.
    Eickhoff, Jens
    Keppen, Michael
    Alberti, Dona B.
    Wilding, George
    Takebe, Naoko
    Liu, Glenn
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (02) : 295 - 302
  • [27] Topotecan/Cisplatin Compared with Cisplatin/Etoposide as First-Line Treatment for Patients with Extensive Disease Small-Cell Lung Cancer Final Results of a Randomized Phase III Trial
    Fink, Thomas H.
    Huber, Rudolf M.
    Heigener, David F.
    Eschbach, Corrina
    Waller, Cornelius
    Steinhauer, Ernst U.
    Virchow, Johann C.
    Eberhardt, Frank
    Schweisfurth, Hans
    Schroeder, Michael
    Ittel, Thomas
    Hummler, Simone
    Banik, Norbert
    Bogenrieder, Thomas
    Acker, Thomas
    Wolf, Martin
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : 1432 - 1439
  • [28] Etoposide plus cisplatin followed by concurrent chemo-radiotherapy and irinotecan plus cisplatin for patients with limited-stage small cell lung cancer: A multicenter phase II study
    Xenidis, N.
    Kotsakis, A.
    Kalykaki, A.
    Christophyllakis, Ch.
    Giassas, S.
    Kentepozidis, N.
    Polyzos, A.
    Chelis, L.
    Vardakis, N.
    Vamvakas, L.
    Georgoulias, V.
    Kakolyris, S.
    LUNG CANCER, 2010, 68 (03) : 450 - 454
  • [29] Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer
    Langer, Corey J.
    Albert, Istvan
    Ross, Helen J.
    Kovacs, Peter
    Blakely, L. Johnetta
    Pajkos, Gabor
    Somfay, Attila
    Zatloukal, Petr
    Kazarnowicz, Andrzei
    Moezi, Mehdi M.
    Schreeder, Marshall T.
    Schnyder, Judy
    Ao-Baslock, Ada
    Pathak, Ashutosh K.
    Berger, Mark S.
    LUNG CANCER, 2014, 85 (03) : 420 - 428
  • [30] A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease
    Zatloukal, P.
    Cardenal, F.
    Szczesna, A.
    Gorbunova, V.
    Moiseyenko, V.
    Zhang, X.
    Cisar, L.
    Soria, J. -C.
    Domine, M.
    Thomas, M.
    ANNALS OF ONCOLOGY, 2010, 21 (09) : 1810 - 1816
12345